26 October 2020: Clinical Research
A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer
Hanzhi Cui 12BCDEF* , Jingzhi Guan 2D* , Guochao Deng 1B , Jiajia Yuan 3B , Changjie Lou 4B , Wen Zhang 5B , Aiping Zhou 5BD , Yanqiao Zhang 4D , Jun Zhou 3D , Guanghai Dai 6ADG*DOI: 10.12659/MSM.927654
Med Sci Monit 2020; 26:e927654
Table 3 Rates of adverse events in patients in the trial.
| Variable | AS (n=211) | AG (n=75) | FOLFIRINOX (n=11) | Total (n=297) | P value | ||||
|---|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | No. | % | ||
| Complete response | 2 | 0.9 | 0 | 0.0 | 0 | 0.0 | 2 | 0.7 | |
| Partial response | 97 | 46.0 | 14 | 18.7 | 0 | 0.0 | 111 | 37.3 | |
| Stable disease | 85 | 40.3 | 38 | 50.7 | 7 | 63.6 | 130 | 43.8 | |
| Progressive disease | 27 | 12.8 | 23 | 30.7 | 4 | 36.4 | 54 | 18.2 | |
| 98 | 46.9 | 14 | 18.7 | 0 | 0.0 | 113 | 38.0 | 0.000 | |
| 184 | 87.2 | 52 | 69.3 | 7 | 63.6 | 243 | 81.8 | 0.001 | |